Recursion’s REC-994 Trial Fully Enrolled
We are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule. Our…
Patient Participation
Learn More About Clinical Trials
Learn more about how clinical trials work, check out some Myths vs Facts and get your questions answered with our FAQs. Still have more questions? Reach out at ClinicalTrials@AllianceToCure.org
New Founder Mutation Identified
CCM2 exon 2-10 deletion research, led by Alliance to Cure Cavernous Malformation families and Duke University, has identified a new founder mutation. Read coverage in the Atlantic magazine. The collaborative…
Alliance to Cure Cavernous Malformation Receives $600,000 Award from the Chan Zuckerberg Initiative to Advance Rare Disease Research
CHARLOTTESVILLE, VA (November 3, 2021) — Today, the Chan Zuckerberg Initiative (CZI) announced $13 million in funding for 40 patient-led, rare disease advocacy organizations that are working alongside researchers and…
Update Your Cavernous Malformation Patient Registry Profile
Update your profile or join now. Why Participate in the Registry? Join the international research community We need you! Clinical research and treatment trials rely on volunteer participants to help…
